(MENAFN- GlobeNewsWire - Nasdaq) Dublin, Nov. 11, 2026 (GLOBE NEWSWIRE) -- "SNP Genotyping and Analysis - Global Strategic Business Report 2026" has been added to ResearchAndMarkets.com's offering. The global SNP genotyping and analysis market was valued at US$38.5 billion in 2025 and is projected to reach US$147.6 billion by 2032, expanding at a compound annual growth rate (CAGR) of 21.2%. Market growth is being supported by rising investment in genomic research, increasing demand for precision medicine, advances in high-throughput genotyping technologies, and broader use across disease diagnostics, pharmacogenomics, agriculture, and biotechnology.
Market Trends and Growth Drivers
SNP genotyping and analysis is increasingly central to genomic research and clinical decision-making. Its ability to identify genetic variants associated with disease susceptibility, treatment response, and biological traits supports applications spanning oncology, cardiovascular disease, diabetes, neurological disorders, reproductive health, and inherited conditions.
The growing adoption of personalized medicine is a major market driver. Healthcare providers and researchers are using SNP analysis to evaluate drug metabolism, efficacy, and safety, enabling more targeted treatment selection and dosing. Pharmacogenomics applications can improve clinical outcomes while reducing the likelihood of adverse drug reactions. Precision medicine initiatives in North America and Europe are accelerating the integration of genomic data into healthcare systems, while adoption is also advancing across Asia-Pacific and other emerging markets.
Increased public- and private-sector investment in genomics is further strengthening demand. Large-scale population studies and biobanks have generated extensive genetic datasets, creating opportunities for advanced SNP genotyping platforms, analytical software, testing services, and clinical applications. The rising incidence and diagnosis of genetic disorders are also increasing demand for accurate genetic testing and risk assessment.
Technology Advancements Expanding Market Applications
Next-generation sequencing, microarray-based genotyping, PCR-based technologies, and whole-genome sequencing are improving the speed, scale, sensitivity, and accuracy of SNP analysis. Microarrays remain important for genome-wide association studies and large-scale screening, while next-generation sequencing enables deeper analysis of rare variants and complex genomic regions.
Bioinformatics, artificial intelligence, and machine learning are becoming increasingly important as organizations seek to interpret large and complex genomic datasets. These technologies support variant identification, functional analysis, biomarker discovery, disease-risk assessment, and therapeutic target development. Integration with gene-expression and epigenetic data is also helping researchers build more comprehensive models of disease biology.
Single-cell genotyping and digital PCR are extending SNP analysis into cancer research, liquid biopsy, prenatal testing, pathogen detection, and developmental biology. In oncology, analysis at the individual-cell level can reveal tumor heterogeneity and clonal evolution, potentially supporting more informed treatment strategies. Digital PCR provides high sensitivity for low-frequency variants and copy-number changes, broadening clinical and research use cases.
Healthcare and Agricultural Adoption
Healthcare represents a critical source of demand for SNP genotyping and analysis solutions. Applications include disease diagnostics, pharmacogenomics, precision medicine, genetic risk assessment, treatment guidance, and patient monitoring. Commercial testing services and wider access to genetic testing are also expanding the addressable market.
Agricultural biotechnology offers another significant growth opportunity. SNP analysis is used in crop and livestock programs to identify genetic markers associated with disease resistance, drought tolerance, productivity, quality, and yield. Marker-assisted selection can accelerate breeding programs and support the development of agricultural varieties suited to changing environmental and commercial requirements. Adoption is particularly relevant in Asia-Pacific and Latin America, where agriculture remains economically important and food-security priorities are driving biotechnology investment.
Report Scope
The report analyzes the global SNP genotyping and analysis market by value in US dollars, covering the following segments:
Sample: Genomic DNA, RNA, cell-free DNA, plasma, and whole blood. Technology: Sanger sequencing, next-generation sequencing, microarray-based genotyping, PCR-based genotyping, and whole-genome sequencing. Application: Disease diagnostics, pharmacogenomics, precision medicine, forensic science, agriculture, and livestock. End Use: Hospitals and clinics, research laboratories, pharmaceutical and biotechnology companies, diagnostic laboratories, and other users. Geography: United States, Canada, Japan, China, Europe, Asia-Pacific, and the rest of the world.
Key Market Insights
The genomic DNA sample segment is projected to reach US$54.1 billion by 2032, advancing at a CAGR of 23.5%. The RNA sample segment is expected to grow at a CAGR of 20.7% during the analysis period. The United States SNP genotyping and analysis market was valued at US$11.5 billion in 2025. China is forecast to expand at a CAGR of 20% and reach US$24.6 billion by 2032. Japan, Canada, Germany, and the wider Asia-Pacific region are expected to provide additional growth opportunities through expanding genomic research and precision medicine programs.
Strategic Value of the Report
Independent market forecasts and annual sales analysis covering 2025 through 2032. Detailed evaluation of major technologies, samples, applications, end users, and geographic markets. Assessment of competitive conditions and the presence of leading companies across key regions. Analysis of market drivers, restraints, emerging technologies, and future opportunities. Actionable intelligence to support investment planning, market entry, product development, and revenue-growth strategies. Company coverage featuring Affymetrix, Inc.; F. Hoffmann-La Roche AG; Fluidigm Corporation; Illumina, Inc.; Life Technologies Corporation; and Sequenom, Inc., among others. Complimentary report updates for one year, providing continued visibility into important market developments.
Domain Expert Insights
The analysis incorporates perspectives from domain experts across industry, enterprise, and academia, adding strategic context beyond conventional secondary research. The report tracks early market signals emerging from expert discussions, company activity, conference sessions, keynote presentations, panel discussions, corporate disclosures, annual reports, institutional publications, and other validated sources.
These inputs are synthesized to identify the direction of the SNP genotyping and analysis market, the forces influencing competitive change, and the developments most likely to affect business strategy. The report also extends beyond market-level findings by examining companies participating in and shaping the competitive landscape.
Market share is assessed where it provides meaningful strategic value. Because competitive structures differ by geography, the analysis may evaluate major regional markets individually rather than relying exclusively on a single global market-share figure. This approach provides a more accurate view of regional competition, technology adoption, commercial positioning, and emerging opportunities through 2032.
Key Attributes
CONTACT:
CONTACT: ResearchAndMarkets.com
Laura Wood,Senior Press Manager...
For E.S.T Office Hours Call 1-917-300-0470
For U.S./ CAN Toll Free Call 1-800-526-8630
For GMT Office Hours Call +353-1-416-8900
Comments
No comment